Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
MIRA Pharmaceuticals has signed a binding letter of intent to acquire SKNY Pharmaceuticals, Inc., as part of its strategy to expand its pipeline into weight loss and smoking cessation drug development. The acquisition is expected to secure a $5 million capital infusion for MIRA Pharmaceuticals to advance these initiatives. The announcement was made on March 24, 2025, and follows a pre-market decline of 7.8% in MIRA's stock price.
MIRA Pharmaceuticals $MIRA Signs To Acquire SKNY Pharmaceuticals, Expand Pipeline Into Weight Loss And Smoking Cessation Drug On Monday, MIRA Pharmaceuticals $MIRA signed a binding letter of intent (LOI) to acquire SKNY Pharmaceuticals, Inc. Please read the full article ⤵️ https://t.co/1TpGf67QIa
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of Binding Letter of Intent with Neurospa TMS Holdings, LLC for Expansion of its Planned International Network of Interventional Psychiatry Clinics $NRXP https://t.co/DdgWOcLQIG
$MIRA (-7.8% pre) EXCLUSIVE: MIRA Pharmaceuticals Signs To Acquire SKNY Pharmaceuticals, Expand Pipeline Into Weight Loss And Smoking Cessation Drug - BZ https://t.co/9fWP4QfTuL
